Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2020 Jun 17;15(6):e0234556.
doi: 10.1371/journal.pone.0234556. eCollection 2020.

Higher prevalence of psoriatic arthritis in the adult population in Spain? A population-based cross-sectional study

Antonio Romero Pérez  1 , Rubén Queiro  2 , Daniel Seoane-Mato  3 , Eduard Graell  4 , Eugenio Chamizo  5 , Lara Chaves Chaparro  5 , Sara Rojas Herrera  5 , Jordi Pons Dolset  6 , Miguel A Polo Ostáriz  6 , Susana Ruiz-Alejos Garrido  6 , Cristina Macía-Villa  7 , Ana Cruz-Valenciano  7 , María L González Gómez  8 , Carlos Sánchez-Piedra  3 , Federico Díaz-González  9   10 , Sagrario Bustabad-Reyes  10 ; Proyecto EPISER2016 Working Group
Affiliations
Multicenter Study

Higher prevalence of psoriatic arthritis in the adult population in Spain? A population-based cross-sectional study

Antonio Romero Pérez et al. PLoS One. .

Abstract

Objective: The prevalence of psoriatic arthritis (PsA) is very heterogeneous. There are no data on its frequency in the general population in Spain. The aim of EPISER2016 study was to estimate the prevalence of PsA in people aged ≥20 years in Spain.

Methods: Cross-sectional multicenter population-based study. Subjects from all the autonomous communities in Spain were randomly selected using multistage stratified cluster sampling. Participants in each of the municipalities randomly selected for the study were administered a telephone-based questionnaire to screen for the study diseases. If the participant reported being previously diagnosed, rheumatologists from the participant's reference hospital confirmed the diagnosis based on a review of the clinical history. Subjects not previously diagnosed but whose screening result was positive based on symptoms received a second telephone call from the investigating rheumatologist in order to evaluate the suspicion. If the suspicion remained, an appointment was made at the reference hospital to complete the diagnostic confirmation process according to CASPAR criteria. To calculate the prevalence and its 95% confidence interval (CI), the sample design was taken into account and weighing was calculated considering age, sex and geographic origin.

Results: The sample comprised 4916 subjects. The prevalence of PsA was 0.58% (95%CI: 0.38-0.87). All but 1 of the 27 cases (96.30%) had been diagnosed prior to EPISER2016.

Conclusion: The prevalence of PsA in Spain was among the highest reported to date, only below that reported in Norway (0.67%) and slightly higher than that reported in Italy (0.42%).

PubMed Disclaimer

Conflict of interest statement

EPISER2016 has been funded by Celgene, Gebro Pharma, Merck Sharp & Dohme in Spain, Pfizer and Sanofi-Aventis. This does not alter our adherence to PLOS ONE policies on sharing data and materials.

Figures

Fig 1
Fig 1. Definition of positive symptom-based screening for psoriatic arthritis.
Fig 2
Fig 2. Results of the recruitment and case detection.
See this image and copyright information in PMC

References

    1. Burgos-Pol R, Martinez-Sesmero JM, Ventura-Cerda JM, Elias I, Caloto MT, Casado MA. The Cost of Psoriasis and Psoriatic Arthritis in 5 European Countries: A Systematic Review. Actas dermosifiliogr. 2016;107:577–90. 10.1016/j.ad.2016.04.018 - DOI - PubMed
    1. Gratacos J, Dauden E, Gomez-Reino J, Moreno JC, Casado MA, Rodriguez-Valverde V. Health-related quality of life in psoriatic arthritis patients in Spain. Reumatol Clin. 2014;10:25–31. 10.1016/j.reuma.2013.05.006 - DOI - PubMed
    1. Scotti L, Franchi M, Marchesoni A, Corrao G. Prevalence and incidence of psoriatic arthritis: A systematic review and meta-analysis. Semin Arthritis Rheum. 2018;48:28–34. 10.1016/j.semarthrit.2018.01.003 - DOI - PubMed
    1. Ferrandiz C, Carrascosa JM, Toro M. Prevalence of psoriasis in Spain in the age of biologics. Actas dermosifiliogr. 2014;105:504–9. 10.1016/j.ad.2013.12.008 - DOI - PubMed
    1. Lopez Estebaranz JL, Zarco-Montejo P, Samaniego ML, Garcia-Calvo C, Group PS. Prevalence and clinical features of psoriatic arthritis in psoriasis patients in Spain. Limitations of PASE as a screening tool. Eur J Dermatol. 2015;25:57–63. 10.1684/ejd.2014.2449 - DOI - PubMed

Publication types